A phase II study of perifosine in patients with relapsed/refractory Waldenstrom's macroglobulinaemia.

Trial Profile

A phase II study of perifosine in patients with relapsed/refractory Waldenstrom's macroglobulinaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Perifosine (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2011 Actual initiation date changed from Sep 2006 to Oct 2006 as reported by ClinicalTrials.gov (NCT00398710).
    • 17 Oct 2011 Actual initiation date changed from Sep 2006 to Oct 2006 as reported by ClinicalTrials.gov (NCT00398710).
    • 17 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00398710).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top